Grants and Contributions:
Title:
UKRI Biomafnufacturing - 10095801 TCR-LNP - Combining long-circulating Lipid Nanoparticles with cancer-targeting T-Cell Receptors
Agreement Number:
1020099
Agreement Value:
$304,000.00
Agreement Date:
Jul 2, 2024 - Mar 1, 2026
Description:
As part of the international consortium project TCR-LNP, this project will involve development of novel formulations of long-circulating lipid nanoparticles (lcLNP) with surface-ligated cancer tumor cell targeting T cell receptor (TCR) proteins to improve cancer-cell specific delivery of mRNA-based payloads.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6T 1Z3
Reference Number:
172-2024-2025-Q2-1020099
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
714010279
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is -144,000 dollars.
Amendment Date
Jan 24, 2025
Recipient's Legal Name:
NanoVation Therapeutics Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: